First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials

被引：1
|
作者：
Doherty, M. [1 ]
Delos Santos, S. [2 ]
Rahmadian, A. Putri [2 ]
Chan, K. [1 ]
机构：
[1] Sunnybrook Odette Canc Ctr, Med Oncol, Toronto, ON, Canada
[2] Sunnybrook Res Inst, Toronto, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
advanced NSCLC; immuno-oncology; immune checkpoint inhibitor;
D O I：
10.1016/j.jtho.2018.08.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-16
引用
收藏
页码：S465 / S466
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials.
    Doherty, Mark
    Delos Santos, Seanthel
    Rahmadian, Amanda Putri
    Everest, Louis
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
    Wan, Ning
    Zhang, Tian-tian
    Hua, Si-hua
    Lu, Zi-luo
    Ji, Bo
    Li, Li-xia
    Lu, Li-qing
    Huang, Wen-jie
    Jiang, Jie
    Li, Jian
    CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
  • [3] Pembrolizumab plus Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis
    Ang, K. F.
    Villafuerte, R. J.
    Regala, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1070 - S1071
  • [4] Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
    Descourt, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1011
  • [5] PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC - A NETWORK META-ANALYSIS
    Frederickson, A. M.
    Arndorfer, S.
    Lorenzi, M.
    Insinga, R.
    Chandwani, S.
    Burke, T.
    VALUE IN HEALTH, 2018, 21 : S20 - S20
  • [6] Efficacy of Nivolumab plus Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis
    O'Byrne, K.
    Popoff, E.
    Badin, F.
    Lee, A.
    Yuan, Y.
    Goring, S.
    Eccles, L. J.
    Varol, N.
    Waser, N.
    Penrod, J. R.
    Lozano-Ortega, G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S629 - S630
  • [7] The Safety of First-line and Subsequent Monotherapy of PD-1/PD-L1 Inhibitors in NSCLC: A Meta Analysis
    Yang, Y.
    Xie, Z.
    Pang, P.
    Wang, N.
    Liang, H.
    Zhao, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1048 - S1049
  • [8] Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
    Facchinetti, Francesco
    Di Maio, Massimo
    Tiseo, Marcello
    CANCERS, 2020, 12 (09) : 1 - 18
  • [9] The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
    Tamiya, M.
    Tamiya, A.
    Hosoya, K.
    Taniguchi, Y.
    Yokoyama, T.
    Fukuda, Y.
    Hirano, K.
    Matsumoto, H.
    Kominami, R.
    Suzuki, H.
    Hirashima, T.
    Uchida, J.
    Morita, M.
    Kanazu, M.
    Sawa, N.
    Hara, S.
    Kinoshita, Y.
    Kumagai, T.
    Fujimoto, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Chemotherapy plus PD-1/PD-L1 inhibitor versus chemotherapy alone in first-line treatment for recurrent or advanced endometrial cancer: A systematic review and meta-analysis of randomized controlled trials
    de Liz, Caio Dabbous
    Maia, Melissa
    Fonseca Alves, Ana Caroline
    Mendes da Silva, Isadora Mamede
    Oliveira, Joao Pedro
    Ferreira de Oliveira, Audrey Cabral
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345